Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
VCEL 
Vericel Corp Ord (VCEL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: VCEL (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $59.38
1 Year Target Price $59.38
| 7 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -33.85% | Avg. Invested days 30 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.10B USD | Price to earnings Ratio 834.6 | 1Y Target Price 59.38 |
Price to earnings Ratio 834.6 | 1Y Target Price 59.38 | ||
Volume (30-day avg) 8 | Beta 1.34 | 52 Weeks Range 37.39 - 63.00 | Updated Date 06/30/2025 |
52 Weeks Range 37.39 - 63.00 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.05 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 1.25% | Operating Margin (TTM) -24.32% |
Management Effectiveness
Return on Assets (TTM) -0.45% | Return on Equity (TTM) 1.13% |
Valuation
Trailing PE 834.6 | Forward PE 454.55 | Enterprise Value 2086877096 | Price to Sales(TTM) 8.81 |
Enterprise Value 2086877096 | Price to Sales(TTM) 8.81 | ||
Enterprise Value to Revenue 8.75 | Enterprise Value to EBITDA 197.77 | Shares Outstanding 50343000 | Shares Floating 49785672 |
Shares Outstanding 50343000 | Shares Floating 49785672 | ||
Percent Insiders 1.06 | Percent Institutions 108.03 |
Analyst Ratings
Rating 3 | Target Price 59.38 | Buy 1 | Strong Buy 7 |
Buy 1 | Strong Buy 7 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Vericel Corp Ord
Company Overview
History and Background
Vericel Corporation focuses on autologous cell therapies for severe burn injuries and cartilage repair. Founded in 1998 as BioSurface Engineering Technologies, changed to Vericel Corporation in 2014. Milestones include FDA approvals for its products and strategic acquisitions.
Core Business Areas
- Burn Care: Vericel's burn care segment focuses on the production and marketing of Epicel, a cultured epidermal autograft used for the treatment of severe burns. The skin cells are taken from the patients body and then grown in a lab.
- Cartilage Repair: Vericel's cartilage repair segment includes MACI (autologous cultured chondrocytes on porcine collagen membrane) for the treatment of cartilage defects in the knee. The cartilage cells are taken from the patients body and then grown in a lab.
Leadership and Structure
The leadership team typically consists of a CEO, CFO, and various vice presidents overseeing operations, research, and marketing. The organizational structure is hierarchical with functional departments. Exact leadership may vary, so check the website.
Top Products and Market Share
Key Offerings
- Epicel: Epicel is a cultured epidermal autograft (CEA) indicated for the treatment of deep dermal or full-thickness burns comprising greater than or equal to 30% total body surface area (TBSA). Limited market share data available publicly. Competitors include skin substitutes and traditional burn treatments, which are many different products from multiple companies.
- MACI: MACI is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple, full-thickness cartilage defects of the knee, with or without bone involvement. Limited market share data available publicly. Competitors include surgical procedures like microfracture, osteochondral autograft transplantation (OATS), and allograft transplantation. Companies with other products in this space include Johnson & Johnson (DePuy Synthes) and Stryker.
Market Dynamics
Industry Overview
The regenerative medicine industry is growing, driven by demand for advanced therapies and minimally invasive procedures. Regulatory hurdles and manufacturing complexities pose challenges. There is also high competition within the space from multiple firms, both large and small.
Positioning
Vericel is positioned as a leader in autologous cell therapies, focusing on specialized applications in burn care and cartilage repair. Its competitive advantage lies in its FDA-approved products and established clinical track record.
Total Addressable Market (TAM)
The TAM for advanced wound care and cartilage repair is estimated to be in the billions of dollars. Vericel's positioning allows it to capture a significant portion of this market, especially in the severe burn and complex cartilage defect segments.
Upturn SWOT Analysis
Strengths
- FDA-approved products (Epicel & MACI)
- Established clinical track record
- Specialized expertise in autologous cell therapies
- Strong market position in niche areas
Weaknesses
- High manufacturing costs
- Limited product pipeline
- Reliance on specialized surgical procedures
- Small sales force limiting the number of doctors it can reach
Opportunities
- Expanding indications for existing products
- Developing new cell therapy products
- Strategic partnerships and acquisitions
- Increasing awareness and adoption of regenerative medicine
Threats
- Regulatory challenges and changes
- Competition from established medical device companies
- Reimbursement pressures from payers
- Technological advancements from competitors
Competitors and Market Share
Key Competitors
- JNJ
- STRY
Competitive Landscape
Vericel's advantages include its specialized focus and established clinical track record. Disadvantages include its smaller size and limited product pipeline compared to larger competitors like JNJ and STRY.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by increasing adoption of Epicel and MACI. The growth rate has varied depending on market conditions and competitive pressures. Provide financial data here.
Future Projections: Future growth is projected to be driven by expanding indications for existing products, strategic partnerships, and increasing awareness of regenerative medicine. Provide analyst estimates here.
Recent Initiatives: Recent initiatives include focusing on increasing sales of MACI and EPICEL, improving manufacturing efficiency, and exploring partnerships.
Summary
Vericel is a specialized cell therapy company with FDA-approved products for burn care and cartilage repair, giving it a strong market position. However, high manufacturing costs and limited product pipeline are concerns. Future growth depends on expanding indications, strategic partnerships, and navigating regulatory challenges in the regenerative medicine sector.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
- Company website
Disclaimers:
This analysis is based on available information and is not financial advice. Market conditions can change rapidly.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Vericel Corp Ord
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 1997-02-04 | CEO, President & Director Mr. Dominick C. Colangelo Esq. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 357 | Website https://www.vcel.com |
Full time employees 357 | Website https://www.vcel.com | ||
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.